HK Stock Market Move | ALPHAMAB-B(09966) rose more than 5%, Enverolizumab for new indications completed Phase III clinical trial enrollment.

ALPHAMAB-B(09966) rose more than 4%, up 4.32% to 9.18 Hong Kong dollars as of press time, with a turnover of 8.1135 million Hong Kong dollars. On the news front, on May 22, Kangning Jierui Biopharmaceuticals announced that the III Phase clinical trial of nevadar (envorlimab injection, Kangning Jierui R&D code: KN035) for neoadjuvant/adjuvant treatment of resectable non-small cell lung cancer (NSCLC) (Study number: KN035-CN-017) has completed enrollment of all patients. This milestone marks significant progress for nevadar in the field of perioperative treatment of early lung cancer, offering a more convenient and safer subcutaneous immunotherapy option for lung cancer patients. Currently, nevadar has several ongoing clinical trials to further expand its indications. The new drug application for the indication of gemcitabine and oxaliplatin (GEMOX) regimen for first-line treatment of unresectable or metastatic bile duct cancer has been accepted by the National Medical Products Administration (NMPA).